Skip to main content

Table 2 Patient demographics from the included studies

From: Sporting participation following the operative management of chondral defects of the knee at mid-term follow up: a systematic review and meta-analysis

  MFX ACI MACI OAT Allograft PRP + PBSC Overall
Studies 5 6 7 8 4 1 29a
Patients (n) 201 240 347 271 197 20 1276
Age in years (SD) 32.0 (± 4.5) 33.1 (± 4.3) 34.9 (± 4.8) 32.6 (± 8.5) 29.5 (± 3.6) 32.7(± 7.5) 32.8 (± 5.7)
Gender (M/F, %) 69/31 68/32 67/33 73/27 58/42 65/35 67/33
BMI NR 24.3 (± 0.5) 26.1 (± 0.8) 25.0 (± 2.5) 25.0 (± 0.6) 26.0 (± 2.7) 25.3 (± 1.0)
Follow up in months (SD) 114.1 (± 51.8) 71.8 (± 15.9) 65.5 (± 17.1) 136.5 (± 47.9) 71.9 (± 0.3) 61.2 (NR) 88.8 (± 42.4)
Preoperative duration of symptoms in months (SD) NR 32.9 (± 5.1) 94.6 (± 15.3) NR 58.4 (± 1.0) 4.3 (NR) 71.9 (± 28.1)
Preoperative mean Tegner score (SD) 3.2 (NR) 3.50 (± 1.3) 1.9 (± 0.5) 2.9 (± 0.0) NR NR 2.5 (± 0.7)
Preoperative mean Lysholm score (SD) 50.7 (± 5.7) 40.5 (± 0.4) 53.8 (± 6.9) 64.7 (± 5.2) 41.0 (± 13.0) NR 52.7 (± 9.3)
Preoperative mean IKDC subjective score (SD) 44.5 (± 2.8) 41.3 (1.4) 40.3 (± 13.4) 34.8 (± 13.5) 38.0 (± 12.0) 50.5 (± 6.3) 42.1 (± 4.0)
Chondral defects
 Size in cm2 (SD) 3.5 (± 0.7) 4.0 (± 1.4) 3.6 (± 1.2) 2.4 (± 0.5) 4.5 (± 1.8) NR 3.4 (± 1.2)
 MFC (n) 99 120 187 155 9 NR 570
 LFC (n) 37 37 74 54 6 NR 217
 Trochlea (n) 13 18 14 16 21 9 90
 Patella (n) 7 68 11 4 12 6 108
  1. NR not reported; MFX microfracture, ACI autologous chondrocyte implantation, MACI matrix-induced autologous chondrocyte implantation, OAT osteochondral autograft transfer, PRP platelet-rich plasma, PBSC peripheral blood stem cells, M male, F female, IKDC international knee documentation committee, MFC medial femoral condyle, LFC lateral femoral condyle. aTwo studies compared more than one biologic technique